Key result
This editorial compares the ALLHAT trial results regarding antihypertensive treatment in patients with chronic kidney disease with previous studies.
Why the study?
Which antihypertensive agents are optimal for cardiovascular disease outcomes in patients with chronic kidney disease?
Which antihypertensive agents are optimal for cardiovascular disease outcomes in patients with chronic kidney disease?
This editorial discusses the implications of the ALLHAT study findings regarding antihypertensive treatment and cardiovascular outcomes in patients with chronic kidney disease.
In this issue, Rahman and colleagues report cardiovascular disease in chronic kidney disease from the randomized study known as ALLHAT. They had previously reported outcomes of kidney disease in this group. Because so many ALLHAT participants had chronic kidney disease, it is the largest study of hypertension treatment in patients with this disorder. This editorial compares ALLHAT results with previous studies of antihypertensive treatment in patients with chronic kidney disease.
No takes yet. Share an insight, caveat, or question.
Levey et al. (2006) conducted an editorial in Chronic kidney disease and hypertension. Antihypertensive treatment was evaluated. This editorial compares the ALLHAT trial results regarding antihypertensive treatment in patients with chronic kidney disease with previous studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: